Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John R Senior

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Annals of Internal Medicine|January 17, 2003
Healthy ranges for alanine aminotransferase levelsJohn R Senior
Pharmacoepidemiology and Drug Safety|March 21, 2013
Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjectsJohn R Senior
Liver International : Official Journal of the International Association for the Study of the Liver|April 4, 2015
New biomarkers for drug-induced liver injury: are they really better? What do they diagnose?John R Senior
Hepatology Communications|February 7, 2018
Some Recollections of the American Association for the Study of Liver Diseases Transformative Decade 1970-1979John R Senior
Toxicologic Pathology|October 28, 2009
Unintended hepatic adverse events associated with cancer chemotherapyJohn R Senior
Hepatology (Baltimore, Md.)|November 25, 2015
Can rechallenge be done safely after mild or moderate drug-induced liver injury?John R Senior
Hepatology (Baltimore, Md.)|May 30, 2008
What is idiosyncratic hepatotoxicity? What is it not?John R Senior
Pharmacoepidemiology and Drug Safety|March 23, 2006
How can 'Hy's law' help the clinician?John R Senior
Clinics in Liver Disease|August 29, 2007
Drug hepatotoxicity from a regulatory perspectiveJohn R Senior
Drug Safety|October 30, 2014
Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challengesJohn R Senior
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Annals of Internal Medicine|January 17, 2003
Healthy ranges for alanine aminotransferase levelsJohn R Senior
Pharmacoepidemiology and Drug Safety|March 21, 2013
Why the threshold criteria should not be modified for detection of possibly serious drug-induced hepatotoxicity in special groups of trial subjectsJohn R Senior
Liver International : Official Journal of the International Association for the Study of the Liver|April 4, 2015
New biomarkers for drug-induced liver injury: are they really better? What do they diagnose?John R Senior
Hepatology Communications|February 7, 2018
Some Recollections of the American Association for the Study of Liver Diseases Transformative Decade 1970-1979John R Senior
Toxicologic Pathology|October 28, 2009
Unintended hepatic adverse events associated with cancer chemotherapyJohn R Senior
Hepatology (Baltimore, Md.)|November 25, 2015
Can rechallenge be done safely after mild or moderate drug-induced liver injury?John R Senior
Hepatology (Baltimore, Md.)|May 30, 2008
What is idiosyncratic hepatotoxicity? What is it not?John R Senior
Pharmacoepidemiology and Drug Safety|March 23, 2006
How can 'Hy's law' help the clinician?John R Senior
Clinics in Liver Disease|August 29, 2007
Drug hepatotoxicity from a regulatory perspectiveJohn R Senior
Drug Safety|October 30, 2014
Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: current status and challengesJohn R Senior
Pageof 2